Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Verinurad. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 known ✓ | Q96S37 | 20/20 | 1.00 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 1.00 |
| ▸ | SLC22A11 | Q9NSA0 | 1/20 | 1.00 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Verinurad SCHEMBL12070797 | 1.00 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL18979018 | 0.94 | SLC22A12 (0.88) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL30109019 | 0.93 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL20587211 | 0.93 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL18979101 | 0.92 | SLC22A12 (0.86) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL15164011 | 0.91 | SLC22A12 (0.83) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| Verinurad SCHEMBL21828465 | 0.89 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL15165680 | 0.88 | SLC22A12 (0.78) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL20020019 | 0.88 | SLC22A12 (0.78) | SLC22A12SLC22A6SLC22A11ABCG2 | |
| SCHEMBL12070799 | 0.86 | SLC22A12 (1.00) | SLC22A12SLC22A6SLC22A11ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731204-A2 | SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | The Trustees Of Columbia University In The City Of New York (US) | 2026-04-29 | — | — | EP | claimed |
| US-12521402-B2 | Biomarker and drug combinations for heart failure prediction | Endothelium Scanning Nanotechnology Limited (AU) | 2026-01-13 | — | — | US | claimed |
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ENDOTHELIUM SCANNING NANOTECHNOLOGY LTD (AU) | 2026-01-01 | — | — | US | claimed |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2026-01-01 | — | — | US | claimed |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-10-14 | — | — | US | claimed |
| WO-2024263790-A2 | NOVEL CO-DRUG, CO-ADMINISTRATION, AND SEQUENTIAL ADMINISTRATION OF SELECTIVE RBP4 ANTAGONIST AND C20-D3-RETINOL FOR ELIMINATION OF MECHANISM-BASED OCULAR ADVERSE EFFECTS IN TREATING MACULAR DEGENERATION, NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), AND GOUTY ARTHRITIS (GOUT) | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2024-12-26 | — | — | WO | claimed |
| EP-4444707-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118541360-A | LPA receptor antagonists and uses thereof | 吉利德科学公司 | 2024-08-23 | — | — | CN | claimed |
| EP-4387647-A2 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | Acceleron Pharma Inc. (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4356142-A1 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | Endothelium Scanning Nanotechnology Limited (AU) | 2024-04-24 | — | — | EP | claimed |
| WO-2023022968-A2 | COMPOSITIONS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | ACCELERON PHARMA INC. (US) | 2023-02-23 | — | — | WO | claimed |
| US-20230037277-A9 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | ASTRAZENECA AB (SE) | 2023-02-02 | — | — | US | claimed |
| EP-4117707-A1 | SINGLE-ARM ACTRIIA AND ACTRIIB HETEROMULTIMERS AND METHODS FOR TREATING RENAL DISEASES OR CONDITIONS | Acceleron Pharma Inc. (US) | 2023-01-18 | — | — | EP | claimed |
| WO-2022261705-A1 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | ESN CLEER (AU) | 2022-12-22 | — | — | WO | claimed |
| EP-4100431-A1 | VARIANT ACTRIIB PROTEINS AND USES THEREOF | Acceleron Pharma Inc. (US) | 2022-12-14 | — | — | EP | claimed |
| WO-2022240879-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| WO-2022241023-A1 | LPA RECEPTOR ANTAGONISTS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2022-11-17 | — | — | WO | claimed |
| EP-4058144-A1 | TRIAZOLE CARBAMATE PYRIDYL SULFONAMIDES AS LPA RECEPTOR ANTAGONISTS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2022-09-21 | — | — | EP | claimed |
| US-20220257522-A1 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | ASTRAZENECA AB (SE) | 2022-08-18 | — | — | US | claimed |
| CN-114728168-A | Triazolecarbamate pyridylsulfonamides as LPA receptor antagonists and their use | 吉利德科学公司 | 2022-07-08 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000679-A9 | BIOMARKER AND DRUG COMBINATIONS FOR HEART FAILURE PREDICTION | NPPA, TNNT2, SLC5A2 | SLC22A12 149/4885SLC22A6 150/4885SLC22A11 180/4885 |
| US-20220257522-A1 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | CEL, PNLIP, SLC10A2 | SLC22A12 1218/4885SLC22A6 405/4885SLC22A11 723/4885 |
| US-20260000663-A1 | RBP4 ANTAGONISTS FOR TREATMENT AND PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND GOUT | RBP4, RBP1, FABP1 | SLC22A12 1765/4885SLC22A6 2050/4885SLC22A11 1415/4885 |
| US-12440486-B2 | RBP4 antagonists for treatment and prevention of non-alcoholic fatty liver disease and gout | RBP4, RBP1, FABP1 | SLC22A12 706/4885SLC22A6 812/4885SLC22A11 752/4885 |
| US-20230037277-A9 | DOSE DUMPING RESISTANT PHARMACEUTICAL COMPOSITIONS COMPRISING VERINURAD | CEL, PNLIP, SLC10A2 | SLC22A12 1218/4885SLC22A6 405/4885SLC22A11 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.